From: Radioimmunotherapy study of 131I-labeled Atezolizumab in preclinical models of colorectal cancer
Model | Treatment modality | Survival | ||
---|---|---|---|---|
Median survival time(d) | P value | Lifespan (%) | ||
RKO | 131I-Atezolizumab (11.1Â MBq) | 29 | 0.326 | 7.4 |
131I-Atezolizumab (37Â MBq) | 34 | 0.027 | 25.92 | |
Normal Control | 27 | – | – | |
HCT8 | 131I-Atezolizumab (37Â MBq) | 42 | 0.290 | 10.52 |
Normal Control | 38 | – | – |